SLSimon M. Lin

Simon M. Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon M. Lin has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Warren Alden Kibbe

    Data Science and Strategy, National Cancer Institute, Bethesda, MD

    2 shared publications
  • A Miller

    Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA

    1 shared publication
  • Andrea Baccarelli

    Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, USA

    1 shared publication
  • Andrew D. Wallace

    Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina, USA

    1 shared publication
  • Dong Fu

    Northwestern University Biomedical Informatics Center (NUBIC), NUCATS, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America

    1 shared publication
  • H Fang

    Office of Scientific Coordination, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA

    1 shared publication

Latest Publications

  • Open Access

    Computational Evidence of NAGNAG Alternative Splicing in Human Large Intergenic Noncoding RNA

    by Xiaoyong Sun, Simon M. Lin, Xiaoyan Yan

    NAGNAG alternative splicing plays an essential role in biological processes and represents a highly adaptable system for posttranslational regulation of gene function. NAGNAG alternative splicing impacts a myriad of biological processes. Previous studies of NAGNAG largely focused on messenger RNA. To the best of our knowledge, this is the first study testing the hypothesis that NAGNAG alternative splicing is also operative in large intergenic noncoding RNA (lincRNA). The RNA-seq data sets from recent deep sequencing studies were queried to test our hypothesis. NAGNAG alternative splicing of human lincRNA was identified while querying two independent RNA-seq data sets. Within these datasets, 31 NAGNAG alternative splicing sites were identified in lincRNA. Notably, most exons of lincRNA containing NAGNAG acceptors were longer than those from protein-coding genes. Furthermore, presence of CAG coding appeared to participate in the splice site selection. Finally, expression of the isoforms of NAGNAG lincRNA exhibited tissue specificity. Together, this study improves our understanding of the NAGNAG alternative splicing in lincRNA.


  • Exploring the FDA Adverse Event Reporting System to Generate Hypotheses for Monitoring of Disease Characteristics

    by H Fang, Z Su, Y Wang, A Miller, Z Liu, P C Howard, W Tong, S M Lin

    The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a database for postmarketing drug safety monitoring and influences changes in FDA safety guidance documents such as drug labels. The number of cases in the FAERS has rapidly increased with the improvement of submission methods and data standards and thus has become an important resource for regulatory science. Although the FAERS has been predominantly used for safety signal detection, this study explored its utility for disease characteristics. Clinical Pharmacology & Therapeutics (2014); 95 5, 496–498. doi:10.1038/clpt.2014.17


  • Open Access

    A Framework for Annotating Human Genome in Disease Context

    by Wei Xu, Huisong Wang, Wenqing Cheng, Dong Fu, Tian Xia, Warren A. Kibbe, Simon M. Lin

    Identification of gene-disease association is crucial to understanding disease mechanism. A rapid increase in biomedical literatures, led by advances of genome-scale technologies, poses challenge for manually-curated-based annotation databases to characterize gene-disease associations effectively and timely. We propose an automatic method-The Disease Ontology Annotation Framework (DOAF) to provide a comprehensive annotation of the human genome using the computable Disease Ontology (DO), the NCBO Annotator service and NCBI Gene Reference Into Function (GeneRIF). DOAF can keep the resulting knowledgebase current by periodically executing automatic pipeline to re-annotate the human genome using the latest DO and GeneRIF releases at any frequency such as daily or monthly. Further, DOAF provides a computable and programmable environment which enables large-scale and integrative analysis by working with external analytic software or online service platforms. A user-friendly web interface (doa.nubic.northwestern.edu) is implemented to allow users to efficiently query, download, and view disease annotations and the underlying evidences.


  • Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro

    by Xiao Zhang, Andrew D. Wallace, Pan Du, Simon Lin, Andrea A. Baccarelli, Hongmei Jiang, Nadereh Jafari, Yinan Zheng, Hehuang Xie, Marcelo Bento Soares, et al.


  • Open Access

    Genomic sequencing in clinical trials

    by Karen K Mestan, Leonard Ilkhanoff, Samdeep Mouli, Simon Lin

    Human genome sequencing is the process by which the exact order of nucleic acid base pairs in the 24 human chromosomes is determined. Since the completion of the Human Genome Project in 2003, genomic sequencing is rapidly becoming a major part of our translational research efforts to understand and improve human health and disease. This article reviews the current and future directions of clinical research with respect to genomic sequencing, a technology that is just beginning to find its way into clinical trials both nationally and worldwide. We highlight the currently available types of genomic sequencing platforms, outline the advantages and disadvantages of each, and compare first- and next-generation techniques with respect to capabilities, quality, and cost. We describe the current geographical distributions and types of disease conditions in which these technologies are used, and how next-generation sequencing is strategically being incorporated into new and existing studies. Lastly, recent major breakthroughs and the ongoing challenges of using genomic sequencing in clinical research are discussed.